COVID-19 studies are our top priority. For all other trials, there is a 4-week delay in processing a trial submitted/resubmitted to the ANZCTR and additional delays for updates of registered trials. We appreciate your patience.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR

Registration number
Ethics application status
Date submitted
Date registered
Date last updated
Date data sharing statement initially provided
Type of registration
Prospectively registered

Titles & IDs
Public title
A study to investigate safety and optimal dose of Dahlia Extract in people with pre-diabetes or type 2 diabetes.
Scientific title
A 4-week, placebo-controlled, dose-ramping study to investigate the safety and optimal dose of Dahlia Extract in people with either pre-diabetes or type 2 diabetes.
Secondary ID [1] 300108 0
Universal Trial Number (UTN)
Trial acronym
Linked study record
ACTRN12617001605381 is a parent study of this study

Health condition
Health condition(s) or problem(s) studied:
Pre Diabetes 315638 0
type 2 Diabetes 315639 0
Condition category
Condition code
Metabolic and Endocrine 313932 313932 0 0
Alternative and Complementary Medicine 314173 314173 0 0
Herbal remedies

Study type
Description of intervention(s) / exposure
The intervention is a Dahlia spp. extract, the subject of previous study described in application ACTRN12617001605381. THis is an oral capsule. This study is a placebo controlled dose-ramping study randomised for dose frequency and time of administration. Participants will be randomised into four equal groups stratified by metformin use and by HbA1c. Each group will then complete a dose-ramping protocol over four weeks as outlined in the protocol. Two groups will receive the extract three times per day and two groups twice per day. For both conditions, one group with take it immediately prior to a meal and the other one hour prior to meals. In week one all participants will receive placebo. In week two the extract dose will be 30mg (BD or TDS as above). week three, 60mg and week four 120mg. Adherence will be monitored with capsule return and count using blister packing for each week. Participants will have a subcutaneous continuous glucose monitor for all four weeks of the study.
Intervention code [1] 316386 0
Treatment: Other
Comparator / control treatment
The placebo is a microcrystalline Cellulose capsule.
Control group

Primary outcome [1] 322324 0
Glucose data from the Libre will be analysed to determine area under the curve for glucose over 24 hours, and divided into 3-5 hour postprandial periods for each meal. Data will be extracted and averaged for days 4-7 of each treatment dose to allow for steady state to be reached.
Timepoint [1] 322324 0
Each timepoint (week 2, 3 and 4) will be analysed relative to the baseline week (week 1). Baseline AUC glucose will be taken as the average of days 4-7 of the first week while participants receiving placebo.
Secondary outcome [1] 378085 0
A secondary analysis will also be conducted to compare BD vs TDS dosing for AUC over 24 hours. An analysis will also be conducted to compare timing of doses before meals, for AUC over the 5-hour post prandial period following meals where a dose has been given.
Timepoint [1] 378085 0
Secondary analyses will compare conditions between groups at the same timepoint for each dose. Ie the average of days 4-7 AUC glucose during each dosage regimen.

Key inclusion criteria
• Males and females 18 years and over
• Pre-diabetes or type 2 diabetes with HbA1c between 45 mmol/mol and 60 mmol/mol
• Willing to maintain a stable lifestyle throughout the study
Minimum age
18 Years
Maximum age
80 Years
Both males and females
Can healthy volunteers participate?
Key exclusion criteria
• Using any diabetes drug other than Metformin
• Previous bariatric surgery
• Pregnancy or breast feeding
• Liver disease or AST/ ALT >3x ULN
• Diabetic nephropathy with an eGFR <60.
• Stage 3 or 4 NYHF heart failure
• Proliferative retinopathy
• Allergy to sports tape
• Any other long-term condition considered inappropriate by principal investigator.

Study design
Purpose of the study
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Participants will be computer randomised into 4 treatment groups with allocation made on sequential basis by staff member not directly involved in the study.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
The statistician who is not involved directly with the study will provide a randomisation list, stratified by metformin use. Simple randomisation using a randomisation table created by computer software (i.e. computerised sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s

The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Other design features
Not Applicable
Type of endpoint(s)
Statistical methods / analysis
Data will be analysed by treatment group.

Recruitment status
Not yet recruiting
Date of first participant enrolment
Date of last participant enrolment
Date of last data collection
Sample size
Accrual to date
Recruitment outside Australia
Country [1] 22188 0
New Zealand
State/province [1] 22188 0

Funding & Sponsors
Funding source category [1] 304552 0
Commercial sector/Industry
Name [1] 304552 0
Aroma NZ
Address [1] 304552 0
12 Senior Place
Christchurch 8062
New Zealand
Country [1] 304552 0
New Zealand
Primary sponsor type
Commercial sector/Industry
Aroma NZ
12 Senior Place
Christchurch 8062
New Zealand
New Zealand
Secondary sponsor category [1] 304836 0
Name [1] 304836 0
Address [1] 304836 0
Country [1] 304836 0

Ethics approval
Ethics application status
Ethics committee name [1] 304979 0
NZ Health and Disability Ethics Committee - Central
Ethics committee address [1] 304979 0
Ministry of Health Health and Disability Ethics Committees PO Box 5013 Wellington 6140
Ethics committee country [1] 304979 0
New Zealand
Date submitted for ethics approval [1] 304979 0
Approval date [1] 304979 0
Ethics approval number [1] 304979 0

Brief summary
We have demonstrated that an extract from the dahlia plant significantly
improved glucose concentrations in diabetic mice and men with pre-diabetes. This study will extend this to test different times of administration, frequency and doses in people with pre-diabetes and type 2 diabetes.
Trial website
Trial related presentations / publications
Public notes

Principal investigator
Name 98842 0
Prof Jeremy Krebs
Address 98842 0
Wellington Hospital Riddiford St Wellington 6021
Country 98842 0
New Zealand
Phone 98842 0
Fax 98842 0
Email 98842 0
Contact person for public queries
Name 98843 0
Dr Amber Parry Strong
Address 98843 0
Wellington Hospital Riddiford St Wellington 6021
Country 98843 0
New Zealand
Phone 98843 0
Fax 98843 0
Email 98843 0
Contact person for scientific queries
Name 98844 0
Prof Jeremy Krebs
Address 98844 0
Wellington Hospital Riddiford St Wellington 6021
Country 98844 0
New Zealand
Phone 98844 0
Fax 98844 0
Email 98844 0

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No/undecided IPD sharing reason/comment
This data is commercially sensitive.
What supporting documents are/will be available?
Study protocol
How or where can supporting documents be obtained?
Type [1] 6203 0
Study protocol
Citation [1] 6203 0
Link [1] 6203 0
Email [1] 6203 0
Other [1] 6203 0
Summary results
No Results